Crocins for ischemic stroke : a review of current evidence

Kiran Shahbaz; Dennis Chang; Xian Zhou; Mitchell Low; Sai Wang Seto; Chung Guang Li

doi:10.3389/fphar.2022.825842

Crocins for ischemic stroke : a review of current evidence

Kiran Shahbaz
, Dennis Chang
, Xian Zhou
, Mitchell Low
, Sai Wang Seto
, Chung Guang Li

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Crocins (CRs) and the related active constituents derived from Crocus sativus L. (Saffron) have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Among CRs, crocin (CR) has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, nuclear factor kappa light chain enhancer of B cells pathway, S100 calcium-binding protein B, interleukin-6 and vascular endothelial growth factor-A. CR is generally safe and well-tolerated. Pharmacokinetic studies indicate that CR has poor bioavailability and needs to convert to crocetin (CC) in order to cross the blood-brain barrier. Clinical studies have shown the efficacy of saffron and CR in treating various conditions, including metabolic syndrome, depression, Alzheimer's disease, and coronary artery disease. There is evidence supporting CR as a treatment for ischemic stroke, although further studies are needed to confirm their efficacy and safety in clinical settings.

Original language	English
Article number	825842
Number of pages	22
Journal	Frontiers in Pharmacology
Volume	13
DOIs	https://doi.org/10.3389/fphar.2022.825842
Publication status	Published - 5 Aug 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Shahbaz, Chang, Zhou, Low, Seto and Li.

Open Access - Access Right Statement

© 2022 Shahbaz, Chang, Zhou, Low, Seto and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3389/fphar.2022.825842

Cite this

@article{a5ffc95a415f46a4ba4f70764281470a,

title = "Crocins for ischemic stroke : a review of current evidence",

abstract = "Crocins (CRs) and the related active constituents derived from Crocus sativus L. (Saffron) have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Among CRs, crocin (CR) has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, nuclear factor kappa light chain enhancer of B cells pathway, S100 calcium-binding protein B, interleukin-6 and vascular endothelial growth factor-A. CR is generally safe and well-tolerated. Pharmacokinetic studies indicate that CR has poor bioavailability and needs to convert to crocetin (CC) in order to cross the blood-brain barrier. Clinical studies have shown the efficacy of saffron and CR in treating various conditions, including metabolic syndrome, depression, Alzheimer's disease, and coronary artery disease. There is evidence supporting CR as a treatment for ischemic stroke, although further studies are needed to confirm their efficacy and safety in clinical settings.",

author = "Kiran Shahbaz and Dennis Chang and Xian Zhou and Mitchell Low and Seto, \{Sai Wang\} and Li, \{Chung Guang\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Shahbaz, Chang, Zhou, Low, Seto and Li.",

year = "2022",

month = aug,

day = "5",

doi = "10.3389/fphar.2022.825842",

language = "English",

volume = "13",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Crocins for ischemic stroke : a review of current evidence

AU - Shahbaz, Kiran

AU - Chang, Dennis

AU - Zhou, Xian

AU - Low, Mitchell

AU - Seto, Sai Wang

AU - Li, Chung Guang

PY - 2022/8/5

Y1 - 2022/8/5

N2 - Crocins (CRs) and the related active constituents derived from Crocus sativus L. (Saffron) have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Among CRs, crocin (CR) has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, nuclear factor kappa light chain enhancer of B cells pathway, S100 calcium-binding protein B, interleukin-6 and vascular endothelial growth factor-A. CR is generally safe and well-tolerated. Pharmacokinetic studies indicate that CR has poor bioavailability and needs to convert to crocetin (CC) in order to cross the blood-brain barrier. Clinical studies have shown the efficacy of saffron and CR in treating various conditions, including metabolic syndrome, depression, Alzheimer's disease, and coronary artery disease. There is evidence supporting CR as a treatment for ischemic stroke, although further studies are needed to confirm their efficacy and safety in clinical settings.

AB - Crocins (CRs) and the related active constituents derived from Crocus sativus L. (Saffron) have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Among CRs, crocin (CR) has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, nuclear factor kappa light chain enhancer of B cells pathway, S100 calcium-binding protein B, interleukin-6 and vascular endothelial growth factor-A. CR is generally safe and well-tolerated. Pharmacokinetic studies indicate that CR has poor bioavailability and needs to convert to crocetin (CC) in order to cross the blood-brain barrier. Clinical studies have shown the efficacy of saffron and CR in treating various conditions, including metabolic syndrome, depression, Alzheimer's disease, and coronary artery disease. There is evidence supporting CR as a treatment for ischemic stroke, although further studies are needed to confirm their efficacy and safety in clinical settings.

UR - https://hdl.handle.net/1959.7/uws:68134

U2 - 10.3389/fphar.2022.825842

DO - 10.3389/fphar.2022.825842

M3 - Article

SN - 1663-9812

VL - 13

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 825842

ER -

Crocins for ischemic stroke : a review of current evidence

Abstract

Bibliographical note

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this